# Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

> **NCT00141843** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 100 (—)

## Conditions studied

- Hemophilia A

## Interventions

- **GENETIC:** ReFacto AF
- **GENETIC:** B-Domain deleted Recombinant Factor VIII
- **GENETIC:** BDDrFVIII

## Key facts

- **NCT ID:** NCT00141843
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 100 (—)
- **Last updated:** 2008-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141843, "Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00141843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*